Verastem (VSTM)
(Delayed Data from NSDQ)
$9.38 USD
+0.17 (1.79%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.35 -0.03 (-0.32%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VSTM 9.38 +0.17(1.79%)
Will VSTM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VSTM
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
Other News for VSTM
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Verastem names John Hayslip as Chief Medical Officer
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting